Key Points: – Celsius acquires Alani Nu for $1.8B, expanding its zero-sugar beverage lineup. – Alani Nu stays under Celsius, with leadership advising for brand continuity. – The deal boosts market reach, blending Alani Nu’s online strength with Celsius’ retail power.
Celsius Holdings, Inc. (Nasdaq: CELH) has finalized its $1.8 billion acquisition of Alani Nutrition LLC (Alani Nu), strengthening its position in the rapidly growing functional beverage market. The deal, which includes $150 million in tax assets, effectively brings the net purchase price to $1.65 billion, paid through a combination of cash and stock. This acquisition expands Celsius’ portfolio of zero-sugar, health-focused energy drinks and positions the company to capitalize on increasing consumer demand for better-for-you beverage options.
Celsius has built a strong brand by catering to fitness-conscious consumers looking for functional energy drinks with zero sugar. With Alani Nu now under its umbrella, the company gains access to an established brand with a loyal following in the health and wellness space. The acquisition aligns with Celsius’ mission to provide innovative and flavorful products that cater to active lifestyles.
“The closing of this transaction further strengthens our ability to grow the energy drink category and reach new consumers who seek better-for-you, functional beverages as a healthier alternative to traditional, sugary energy drinks,” said John Fieldly, Chairman and CEO of Celsius Holdings.
Alani Nu, co-founded by fitness influencer Katy Hearn, has rapidly grown into a recognizable name in the industry, offering a variety of products including energy drinks, protein powders, and supplements. The brand’s appeal among health-conscious consumers makes it a natural fit within Celsius’ growing portfolio.
Under the terms of the deal, Alani Nu will continue to operate within Celsius, ensuring continuity in branding and product offerings. Key leadership members from Alani Nu will serve as advisors to Celsius, helping to maintain the brand’s identity while leveraging Celsius’ infrastructure and distribution network to expand its reach.
“Alani Nu has built a strong brand and a differentiated consumer base, which we believe will thrive and grow within the Celsius family,” said Alani Nu co-founder Max Clemons. “Thank you to the many Alani Nu employees and partners who have helped inspire and support our customers in their pursuit of active, wellness lifestyles. I look forward to working with the Celsius team to make Alani Nu products available to many more people and to continue creating great-tasting, functional products aligned with today’s wellness lifestyles.”
This acquisition is expected to unlock significant growth opportunities for both brands. Celsius’ established presence in retail and convenience store channels will provide Alani Nu with broader distribution, while Alani Nu’s strong online and direct-to-consumer business will complement Celsius’ expansion efforts.
The global energy drink and functional beverage market has seen substantial growth as consumers increasingly seek out healthier alternatives. With the addition of Alani Nu, Celsius is well-positioned to compete with industry giants like Monster and Red Bull by offering a broader range of health-conscious products.
As Celsius continues to innovate and expand, this acquisition sets the stage for increased market penetration, product innovation, and consumer engagement. By combining forces, Celsius and Alani Nu aim to reshape the functional beverage landscape and provide more options for those seeking energy and wellness in their drinks.
Key Points: – Job openings fell to 7.57 million, the lowest level since September 2024, signaling a cooling labor market. – Hiring remained flat while the quits rate declined, indicating weaker worker confidence. – Consumer concerns about unemployment are rising, with surveys showing the highest job loss expectations since 2009.
The US labor market showed further signs of cooling in February as job openings fell to their lowest level since September 2024. According to the latest Bureau of Labor Statistics (BLS) report, job openings dropped to 7.57 million, down from 7.76 million in January. This marks one of the lowest levels since early 2021 and continues the trend of a gradually slowing labor market.
Labor Market Adjusting to New Economic Reality
The decline in job openings signals a shift in employer demand, potentially in response to higher interest rates and economic uncertainty. Despite this, the labor market remains stable enough that the Federal Reserve is unlikely to adjust its stance on interest rates in the near term.
Oxford Economics lead US economist Nancy Vanden Houten noted, “The February JOLTS report showed some cooling of labor market conditions but is unlikely to sway the Federal Reserve from its view that the job market is stable enough to withstand an extended period of unchanged interest rates as the central bank monitors progress on inflation.”
The Federal Reserve is closely monitoring these labor market trends as it weighs potential rate cuts. According to the CME FedWatch Tool, investors currently see a 66% chance of a rate cut by the Fed’s June meeting.
Hiring and Quit Rates Near Decade Lows
The JOLTS report also highlighted that hiring remained relatively flat, with 5.4 million new hires in February, up slightly from January’s 5.39 million. The hiring rate held steady at 3.4%.
Meanwhile, the quits rate—a measure of worker confidence in the job market—fell to 2% from 2.1% in the prior month. Both the hiring and quits rates are hovering near decade lows, which raises concerns about future labor market weakness.
Kristina Hooper, chief global market strategist at Invesco, warned that a further slowdown in hiring and an increase in layoffs could pose risks to the economy. “If we think we’re going to see layoffs increase, which I very much anticipate going forward, and we continue to have pretty tepid job growth, that’s a problem,” Hooper said. She added that this situation could increase the risk of stagflation or a broader economic slowdown.
Public sentiment about the labor market is also turning negative. A recent survey from the University of Michigan showed that two-thirds of respondents expect the unemployment rate to rise within the next year—the highest reading since 2009.
In another sign of weakening labor demand, the Institute for Supply Management’s manufacturing employment index fell to 44.7% in February, its lowest level since September 2024.
Despite these concerns, official labor data has yet to reflect significant job losses. Economists expect the March employment report, set for release on Friday, to show a net gain of 140,000 jobs, slightly lower than February’s 151,000. The unemployment rate is projected to remain steady at 4.1%.
With job openings declining and consumer sentiment weakening, all eyes are on the upcoming labor reports to see whether the slowdown deepens or if the job market can maintain stability in the coming months.
Key Points: – Endeavour Silver enters Peru with a new silver-gold project, expanding beyond Mexico. – Diversifies operations in a top silver-producing country for long-term growth. – Strong exploration potential with high-grade mineralization and existing infrastructure.
Endeavour Silver, a mid-tier silver producer with operations primarily in Mexico, has signed an agreement to acquire a high-potential project in Peru. The acquisition aligns with the company’s long-term goal of diversifying its portfolio beyond Mexico while increasing its production pipeline.
The newly acquired project is located in a historically prolific mining district known for its high-grade silver and gold deposits. With existing infrastructure and promising exploration potential, the site offers Endeavour an opportunity to accelerate development while leveraging its operational expertise in underground silver mining.
For Endeavour Silver, expanding into Peru is a natural progression. The company has successfully built and operated several silver mines in Mexico, including its flagship Guanaceví and Bolañitos operations. By entering Peru, one of the world’s top silver-producing nations, Endeavour is positioning itself for sustainable growth amid rising global demand for silver and gold.
The deal also reduces the company’s reliance on a single jurisdiction, a move that could mitigate geopolitical risks associated with operating exclusively in Mexico. With silver prices showing strength due to increasing industrial and investment demand, Endeavour Silver’s expansion comes at an opportune time.
The newly acquired project boasts a combination of historical high-grade production and strong exploration upside. Preliminary geological assessments indicate the presence of high-quality silver and gold mineralization, suggesting strong resource expansion potential.
Endeavour Silver plans to commence a detailed exploration program, including drilling and metallurgical testing, to assess the project’s full potential. Depending on results, the company aims to advance toward development and production in the coming years.
For investors, Endeavour Silver’s move into Peru signals a commitment to long-term growth and value creation. Expanding into a new mining-friendly jurisdiction with a high-potential project could enhance the company’s production profile and profitability.
The announcement also underscores the broader trend of small and mid-cap miners looking beyond their traditional operating regions to capitalize on attractive, underdeveloped assets. As silver demand remains strong due to its industrial applications (such as in solar panels and electronics) and investment appeal, Endeavour’s strategic expansion could position it as a key player in the evolving market.
Endeavour Silver’s acquisition in Peru is a bold step that could redefine its future. By entering a world-class mining jurisdiction with a high-grade project, the company is strengthening its asset base while de-risking its geographic exposure. With exploration efforts set to begin, investors will be watching closely to see how the company unlocks value from this newly acquired asset.
Key Points: – Gold prices hit a record $3,128.06 per ounce, driven by geopolitical risks and economic uncertainty. – Investors are bracing for new U.S. tariffs, which could further fuel safe-haven demand. – Analysts expect gold to reach $3,300 per ounce by the end of 2025.
Gold prices have skyrocketed to record highs, surpassing $3,100 per ounce as a wave of economic and geopolitical uncertainty fuels demand for the precious metal. Spot gold hit a new all-time high of $3,128.06 on Monday, marking one of the most significant rallies in its history. The surge comes amid expectations of fresh U.S. tariffs, a shifting Federal Reserve policy, and persistent global tensions, all of which have reinforced gold’s role as a safe-haven asset.
The metal has posted 19 all-time highs in 2025, with seven exceeding the unprecedented $3,000 mark. Prices are up 18% this year, following a 27% surge in 2024. The sharp rise has been attributed to strong central bank purchases, heightened inflation concerns, and a growing shift toward gold-backed exchange-traded funds (ETFs). Analysts believe the rally has momentum, given the broader macroeconomic environment.
Investors are closely watching upcoming U.S. trade policy decisions. President Donald Trump is set to announce new reciprocal tariffs on April 2, with automobile tariffs following on April 3. The prospect of escalating trade tensions is further amplifying gold’s appeal as a hedge against economic instability. “Gold’s rally has been fueled by escalating geopolitical tensions, inflation concerns, and strong investor demand,” said Alexander Zumpfe, a precious metals trader at Heraeus Metals Germany. “Given the current macroeconomic environment—particularly trade war uncertainties and central bank policies—this trend appears sustainable in the near term.”
Geopolitical instability has played a crucial role in gold’s ascent. With ongoing hostilities in the Middle East and no clear resolution to the Russia-Ukraine conflict, safe-haven demand remains strong. Trump’s recent remarks regarding Russia, Iran, and even Greenland have further unsettled markets, driving additional inflows into gold. “Geopolitical uncertainty is high, and Trump’s weekend comments have only increased the global risk environment, enhancing gold’s appeal,” said Nikos Tzabouras, senior market analyst at Tradu.com.
The Federal Reserve’s monetary policy shift is also contributing to gold’s strength. The central bank cut interest rates by 50 basis points last September, and officials anticipate two more rate cuts by the end of 2025. A lower rate environment tends to weaken the U.S. dollar, making gold more attractive as an alternative store of value. Despite this, some analysts argue that central banks’ rising gold purchases are less about losing confidence in the dollar and more about diversification. “Whilst buying gold may reduce central banks’ overall exposure to the dollar, we don’t think this surge reflects a severe loss of confidence in the greenback,” analysts at Capital Economics noted. They predict gold will reach $3,300 per ounce by year-end.
Investor appetite for gold remains strong, with ETFs seeing their largest weekly inflows since March 2022. While North American ETFs have benefited, demand from European investors has also surged due to political uncertainties. With gold’s record-breaking rally showing no immediate signs of slowing, market participants continue to seek safety in the metal amid a turbulent economic landscape.
Key Points: – Braze is acquiring AI decisioning company OfferFit for $325 million. – OfferFit’s reinforcement learning technology will enhance Braze’s AI-powered personalization. – The acquisition supports Braze’s vision for AI-driven customer engagement and experimentation.
Braze (Nasdaq: BRZE), a leading customer engagement platform, has announced its acquisition of OfferFit, an AI decisioning company, for $325 million. The acquisition, expected to close by the end of July 2025, represents a significant step in Braze’s mission to enhance AI-powered personalization, customer journey optimization, and marketing automation.
OfferFit specializes in AI decisioning agents that replace traditional A/B testing with reinforcement learning, allowing brands to automate experimentation and optimize customer interactions in real time. By integrating OfferFit’s technology into its platform, Braze aims to accelerate the evolution of AI-driven engagement, enabling brands to deliver more relevant and personalized customer experiences across multiple channels.
A New Era of AI-Powered Customer Engagement
Braze has long been at the forefront of AI-driven marketing, using machine learning and automation to refine customer interactions. In September 2024, the company introduced Project Catalyst, an initiative designed to leverage AI agents for personalizing customer journeys, content, and incentives. OfferFit’s multi-agent AI system will further enhance these efforts, helping Braze create an even more intelligent and adaptive marketing platform.
“From the beginning, our real-time stream processing technology differentiated Braze’s modern approach to cross-channel customer engagement,” said Braze CEO Bill Magnuson. “Now, with OfferFit’s reinforcement learning technology, we’re taking another leap forward. AI decisioning agents will help brands automatically understand customer behavior, engage them more effectively, and strengthen relationships through intelligent optimization.”
OfferFit has already demonstrated significant success in the AI-driven personalization space. Brands using its technology have seen improved marketing performance by customizing outreach based on hundreds of unique characteristics. For example, companies have used OfferFit’s AI to optimize reactivation campaigns for inactive users or personalize emails to increase new customer signups.
Strategic Benefits and Industry Implications
With this acquisition, Braze is positioning itself as a leader in AI-powered customer engagement at a time when marketers are increasingly turning to automation and machine learning to drive results. OfferFit’s expertise will allow Braze to provide more sophisticated AI-powered tools, helping businesses move beyond manual segmentation and A/B testing to truly individualized marketing strategies.
OfferFit CEO George Khachatryan emphasized the alignment between the two companies. “Like Braze, OfferFit was built to apply advanced technology to the hardest problems that marketers face,” he said. “As a long-time technology partner of Braze, we knew our products were complementary. This acquisition will allow us to scale our AI decisioning technology more rapidly and bring even greater value to Braze’s global customer base.”
Under the terms of the agreement, Braze will acquire OfferFit in a cash and stock transaction. Goldman Sachs & Co. LLC is serving as financial advisor to Braze, with Davis Polk & Wardwell LLP providing legal counsel. OfferFit is being advised by Atlas Technology Group and Latham & Watkins LLP.
The acquisition highlights Braze’s commitment to AI innovation, reinforcing its position as a key player in the rapidly evolving marketing technology landscape. Investors and industry stakeholders will gain further insights during Braze’s Fourth Quarter Fiscal Year 2025 Financial Results Conference Call. As AI continues to reshape marketing, this acquisition signals a new chapter in customer engagement, where automation, data-driven insights, and personalization take center stage.
Key Points: – Core inflation rose 2.8% in February, exceeding expectations, while consumer spending increased 0.4%. – Consumer sentiment dropped to its lowest level since 2022, with growing fears about the labor market. – The Federal Reserve remains cautious on rate cuts as inflation remains above its 2% target.
The U.S. economy continues to face challenges as inflation remains higher than expected while consumer sentiment has dropped to its lowest level in more than two years. Recent data from the Commerce Department and the University of Michigan highlight ongoing concerns about rising prices, slowing consumer spending, and a weakening labor market.
The Federal Reserve’s preferred inflation measure, the core Personal Consumption Expenditures (PCE) price index, rose 0.4% in February, bringing the annual rate to 2.8%. Both figures exceeded economists’ expectations, marking the biggest monthly gain since early 2024. The broader PCE index, which includes food and energy, rose 0.3% on the month and 2.5% year-over-year, in line with forecasts. Goods prices increased 0.2%, led by recreational goods and vehicles, while services prices climbed 0.4%. Gasoline prices provided some relief, declining 0.8%.
Consumer spending increased 0.4% in February, slightly below the 0.5% forecast, despite a stronger-than-expected rise in personal income of 0.8%. While Americans are earning more, they remain cautious about their spending, with the personal savings rate rising to 4.6%, the highest level since June 2024. The stock market reacted negatively to the inflation data, with futures briefly declining as investors weighed the possibility of prolonged higher interest rates.
At the same time, consumer sentiment has weakened. The University of Michigan’s sentiment index fell to 57 in March, the lowest reading since November 2022. A key measure of consumer expectations for the economy dropped to 52.6, signaling growing uncertainty about financial conditions. Labor market concerns are increasing, with two-thirds of consumers expecting unemployment to rise in the coming year, the highest level since 2009. While February’s job report showed 151,000 jobs added and an unemployment rate of 4.1%, underlying data suggests hiring may be slowing. Indicators such as declining job postings and fewer workers voluntarily leaving jobs point to reduced confidence in the labor market.
The Federal Reserve now faces a difficult decision. After cutting rates by a full percentage point in 2024, the central bank has held off on further moves this year. Policymakers are closely monitoring inflation, particularly as President Trump’s proposed tariffs could increase costs across multiple sectors. While tariffs are generally viewed as one-time price shocks rather than ongoing inflationary forces, the scope of Trump’s trade policies and the potential for a broader trade war add uncertainty to the outlook.
For now, the Fed is likely to maintain its cautious stance, balancing inflation concerns with signs of weakening consumer confidence and labor market risks. If economic conditions deteriorate further, discussions around potential rate cuts may gain traction. However, as inflation remains above the central bank’s 2% target, policymakers are hesitant to move too quickly.
With inflation pressures persisting and consumer sentiment weakening, the economic outlook remains uncertain. Higher prices and job market concerns could weigh on consumer spending in the coming months, potentially slowing economic growth. Investors and businesses will be closely watching for signals from the Fed as it navigates a delicate balancing act between inflation control and economic
Key Points: – Oil prices remain vulnerable to the global trade war, impacting Gulf economies dependent on crude exports. – Currency pegs to the U.S. dollar pose challenges, particularly for countries with high external debt. – New trade corridors, particularly between the Gulf and Asia, offer potential opportunities amid shifting global supply chains.
The Middle East has largely avoided direct tariffs in the ongoing global trade war, but its economies remain vulnerable to broader economic shifts. With oil demand at risk, currency pressures mounting, and global trade flows changing, the region must navigate an increasingly uncertain landscape while also seizing new opportunities.
One of the most immediate concerns for the Middle East is oil. While a weaker U.S. dollar initially benefits oil-exporting nations by making crude cheaper for foreign buyers, tariffs and economic slowdowns could lead to lower global demand. Brent crude prices remain sensitive to global trade conditions, and a prolonged trade war could weigh on revenues for major producers like Saudi Arabia and the UAE. Despite efforts to diversify their economies, oil remains the backbone of many Gulf nations, making them particularly exposed to shifts in global demand.
Another challenge comes from currency pegs. Several Gulf states, including Saudi Arabia, the UAE, Qatar, Oman, and Bahrain, have their currencies tied to the U.S. dollar. As the dollar fluctuates in response to tariffs and economic policies, these countries face higher import costs. This could lead to inflationary pressures, especially in economies heavily reliant on imported goods. At the same time, countries with significant external debt, such as Lebanon, Jordan, and Egypt, could struggle with higher debt-servicing costs if the dollar strengthens further.
Trade tensions also pose risks to regional trade hubs like the UAE, which depend on global trade flows. As a logistics and financial center, Dubai has built its economy around international commerce, meaning a prolonged global slowdown could impact its growth. Economists warn that while Gulf economies have taken steps to diversify, the effects of reduced trade volumes could still be felt.
However, the situation is not entirely negative. The trade war has also encouraged the creation of new trade corridors, particularly between the Gulf and Asia. The GCC-Asia trade relationship has seen sustained growth, with increasing investment and business ties. China’s Belt and Road Initiative has already deepened economic connections, and as global supply chains shift, Middle Eastern economies could benefit from a larger role in these emerging trade networks.
Political factors could also play a role in shaping the region’s economic resilience. U.S. President Donald Trump has maintained strong ties with Gulf nations, particularly Saudi Arabia, and has shown an interest in keeping them aligned with U.S. economic and geopolitical priorities. This relationship may provide some buffer against trade war fallout, as evidenced by Jordan’s ability to secure exemptions from certain U.S. tariffs due to its strategic importance.
Looking ahead, Middle Eastern economies must continue to adapt to changing global conditions. Strengthening domestic demand, securing diversified trade partnerships, and managing currency risks will be key strategies for mitigating potential downturns. While challenges remain, opportunities exist for the region to carve out a more influential role in global trade as supply chains and economic alliances shift.
Key Points: – U.S.-based production shields Tesla from Trump’s auto tariffs, unlike GM and Ford. – Musk says ending tax credits would hurt rivals more than Tesla. – Musk sees self-driving tech as Tesla’s key long-term value.
President Donald Trump’s latest move to impose 25% tariffs on foreign automobiles and certain auto parts has shaken the auto industry, sending shares of major automakers tumbling. General Motors (GM) stock fell nearly 7%, while Ford (F) dropped 3%. But Tesla (TSLA) went in the opposite direction, climbing 5% in early trading, as analysts suggested the EV leader may be a “relative winner” in the tariff battle.
Unlike many of its competitors, Tesla is largely insulated from the impact of Trump’s tariffs thanks to its U.S.-based production. While the company operates gigafactories in China and Germany, none of the EVs built at those sites are sold in the U.S. Instead, Tesla’s American customers receive vehicles manufactured in Fremont, California, or Austin, Texas. This domestic production model allows Tesla to avoid the direct cost increases that automakers relying on foreign imports will now face.
By comparison, 77% of Ford’s vehicles are made in the U.S., followed by Stellantis (57%), Nissan (52%), and GM (52%). Many of these companies now find themselves in a difficult position, forced to absorb higher costs or pass them on to consumers. According to TD Cowen analyst Itay Michaeli, Tesla stands to benefit as its competitors struggle with price hikes. In particular, Tesla’s Model Y, a leading seller in the midsize crossover category, faces competition in a segment where nearly half of vehicles could now be subject to tariffs.
Despite Tesla’s apparent advantage, CEO Elon Musk has downplayed the impact of the tariffs on the company. In a post on X, Musk stated that Tesla is “NOT unscathed here” and that the impact on the company remains “significant.” However, he did not elaborate on how or why Tesla might be affected. While the new policy appears to hit Tesla’s competitors far harder, Musk’s comments suggest the company is still navigating challenges related to supply chains and international trade.
Trump, for his part, confirmed that he did not consult Musk before finalizing the tariffs, suggesting that the billionaire CEO “may have a conflict.” While Trump did not clarify the statement, it raises questions about whether Tesla’s relatively strong position under the new policy influenced the decision to exclude Musk from discussions.
Beyond tariffs, another potential battleground is the federal EV tax credit. Under the Inflation Reduction Act signed by President Biden in 2022, buyers can receive up to $7,500 in tax credits for purchasing an electric vehicle. Tesla has benefited from these incentives for years, particularly in its early days when it relied on federal subsidies to boost demand. However, Musk has previously indicated that Tesla no longer depends on these credits. He even suggested that if Trump and a Republican-controlled Congress were to eliminate them, it would hurt Tesla’s competitors far more than Tesla itself.
“I think it would be devastating for our competitors and for Tesla slightly. But long term, probably actually helps Tesla, would be my guess,” Musk said during Tesla’s Q2 earnings call last year.
The bigger bet for Tesla, however, isn’t just EVs—it’s autonomy. Musk has repeatedly stated that self-driving technology is Tesla’s true long-term value driver, not car sales. If Trump’s administration eases regulations around self-driving and robotaxi deployment, Tesla could benefit significantly.
For now, investors seem to agree with Musk. While traditional automakers scramble to reassess their supply chains and pricing strategies, Tesla’s stock continues to rise, reinforcing its position as one of the few beneficiaries of Trump’s aggressive trade policies.
Breakthroughs breathe new life into legacy systems as agencies look for platforms to safely run AI models with sensitive data, ISG Provider Lens™ report says
STAMFORD, Conn.–(BUSINESS WIRE)– State and local governments in the U.S. are reevaluating mainframes as strategic assets and revisiting choices between reengineering and cloud migration, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III ), a global AI-centered technology research and advisory firm.
The 2025 ISG Provider Lens™ Mainframe — Services and Solutions report for the U.S. public sector finds that AI is beginning to make mainframes easier and less expensive to maintain. Agencies are also discovering that mainframes may be uniquely suited to running AI workloads while protecting mission-critical data. Advances in AI created a wave of public-sector interest in mainframes in 2024 that is expected to continue into 2025.
“AI offers a wealth of new options to help the public sector unleash the potential of mainframe systems,” said Nathan Frey, ISG partner and lead, U.S. Public Sector. “When agencies weigh those possibilities against the risks of moving data and applications that have run on mainframes for decades, they often reconsider their roadmaps.”
State, local and educational (SLED) agencies in the U.S. are now considering which applications to keep on mainframes, how to optimize those applications and how to efficiently access mainframe data for use with AI models, the report says. AI, including generative AI, can streamline software development, testing and documentation, making it easier to either refactor or maintain mainframe applications. AI code assistants and chatbots can reduce the impact of the mainframe skills shortage by helping newer developers get up to speed.
More agencies are exploring the potential of AI and gaining a new appreciation for mainframes’ formidable processing and data management capabilities. The Trump administration’s avowed goal of reducing the size and influence of the federal government is expected to increase interest in using AI for automation. State and local governments are considering the same as they face tight budgets and the possibility of taking over some federal functions.
Policies on offshoring state and local government data and computing are also changing, the report says. New hybrid cloud architectures make it easier to use resources outside the U.S. for cost savings while complying with regulations. DevOps methodologies offer new ways to segregate highly sensitive information, which needs to remain on premises or in the U.S., from less sensitive data that can safely be stored offshore.
Rising U.S. public-sector demand for mainframe services has attracted more providers to this market. However, as agencies increase their reliance on providers, they are gravitating toward those that have built up experience in the sector and that understand its unique mainframe requirements.
“State and local agencies in the U.S. are finally rising to the challenge of modernizing age-old mainframe IT environments,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Leading service providers have the AI tools and specialized skills to help them make the leap.”
The report also explores other mainframe trends in the U.S. public sector, including rising IT collaboration among SLED agencies around the country and the impact of new training initiatives by providers.
For more insights into the mainframe challenges faced by the U.S. public sector, including software licensing issues and national political uncertainty, plus ISG’s advice for addressing them, see the ISG Provider Lens™ Focal Points briefing here.
The 2025 ISG Provider Lens™ Mainframe — Services and Solutions report for the U.S. public sector evaluates the capabilities of 29 providers across four quadrants: Mainframe Optimization Services, Application Modernization Services, Mainframe as a Service and Mainframe Operations.
The report names Wipro as a Leader in all four quadrants. It names DXC Technology, Ensono, Kyndryl and TCS as Leaders in three quadrants each. Accenture, FNTS and Infosys are named as Leaders in two quadrants each. Avanade, Capgemini, HCLTech, NTT DATA and Tech Mahindra are named as Leaders in one quadrant each.
In addition, DXC Technology is named as a Rising Star — a company with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant.
In the area of customer experience, UST is named the global ISG CX Star Performer for 2024 among mainframe service providers. UST earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.
Customized versions of the report are available from FNTS and RecoveryPoint.
The 2025 ISG Provider Lens™ Mainframe — Services and Solutions report for the U.S. public sector is available to subscribers or for one-time purchase on this webpage.
About ISG Provider Lens™ Research
The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.
About ISG
ISG (Nasdaq: III ) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
Source: Information Services Group, Inc.View all news
CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present a poster at the AAPM 2025 Annual Meeting, PainConnect, in Austin, Texas on April 5, 2025, at 11:45 a.m. CT. The meeting will take place from April 3-6, 2025.
Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the National Institute on Drug Abuse. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.
Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.
Important Safety Information
Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:
discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.
Do not use Zembrace or Tosymra if you have:
history of heart problems
narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
uncontrolled high blood pressure
hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
severe liver problems
taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
an allergy to sumatriptan or any of the components of Zembrace or Tosymra
Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.
Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.
Zembrace and Tosymra may cause serious side effects including:
changes in color or sensation in your fingers and toes
sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
hives (itchy bumps); swelling of your tongue, mouth, or throat
seizures even in people who have never had seizures before
The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).
Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.
This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.
You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial” in the Journal of Clinical and Translational Hepatology. This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B (“CHB”). The published protocol outlines patient inclusion criteria, randomization and blinding processes, key assessments, and the statistical analysis plan.
The randomized, double-blind, placebo-controlled, multicenter Phase 3 trial (NCT05115942) completed the enrollment of 248 patients across 44 clinical research hospitals in the People’s Republic of China (“PRC”) in October 2024. Patients were randomized 1:1 to receive either F351 or placebo in addition to entecavir antiviral basic therapy for CHB. The primary endpoint is a decrease in liver fibrosis (as measured by the Ishak Scoring System) by at least one stage after 52 weeks of treatment relative to baseline.
The PRC’s National Medical Products Administration (“NMPA”) designated F351 as a “Breakthrough Therapy” in 2021. Gyre expects to report topline results from this Phase 3 trial in the second quarter of 2025.
About Hydronidone (F351)
F351 is a next-generation anti-fibrotic compound and a structural analogue of Pirfenidone, the first approved treatment for idiopathic pulmonary fibrosis (“IPF”) in Japan, the European Union, the United States and the PRC. F351’s dual mechanism has been shown to inhibit in vitro p38γ kinase activity and TGF-β1-driven collagen overproduction—both key drivers of liver fibrosis. F351 specifically targets hepatic stellate cells (“HSCs”), which are central to the progression of fibrosis. In preclinical studies, it has shown strong anti-proliferative and anti-fibrotic effects on HSCs. These effects have been validated across multiple in vivo models of liver fibrosis, including CCl4-induced liver fibrosis in mice, DMN- and HSA-induced liver fibrosis in rats, and a mouse model of MASH fibrosis (a form of MASH with fibrosis) induced by CCl4 plus a Western high-fat diet. Together, these results highlight F351’s potential as a differentiated treatment for liver fibrosis, with a unique mechanism and strong preclinical and clinical evidence supporting its advancement into later-stage development.
About Gyre Pharmaceuticals
Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2024 net sales of $105.8 million). In addition, Gyre Pharmaceuticals is evaluating F351 in a Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC, which is expected to readout topline data by Q2 2025. F351 received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, DKD, COPD, PAH and ALF/ACLF. In October 2023, Gyre Therapeutics acquired an indirect majority interest in Gyre Pharmaceuticals (also known as Beijing Continent Pharmaceuticals Co., Ltd.).
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, with a primary focus on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the U.S. Gyre’s development strategy for F351 in MASH is based on the company’s experience in MASH rodent model mechanistic studies and CHB-induced liver fibrosis clinical studies. Gyre is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230.
Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the expectations regarding Gyre’s research and development efforts and timing of expected clinical readouts, including timing of topline data from Gyre Pharmaceuticals’ Phase 3 clinical trial evaluating F351 for the treatment of CHB-associated liver fibrosis in the PRC. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings the Company may make with the Securities and Exchange Commission.
Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Key Points Summary: – Waraba Gold is acquiring up to an 80% stake in Somaco Global Resources, gaining access to prospective gold and manganese licences in northern Ivory Coast. – The deal involves a $500,000 initial payment, $1.5 million over two years, and $5 million in exploration commitments, alongside issuing six million common shares. – Waraba has suspended operations in Mali due to security concerns but remains committed to resuming activities when conditions improve.
Canadian mineral exploration company Waraba Gold has entered into an earn-in agreement to acquire up to an 80% stake in Somaco Global Resources, a move that strengthens its footprint in the West African mining sector. Somaco Global holds two highly prospective gold licence applications in northern Ivory Coast, a region known for its rich mineral deposits. These include the Sirasso licence and the Tengrela & Tiegba licences, both located near existing gold mines and mineralized shear zones.
One of the most significant assets in this deal is the Sirasso licence, covering 369.34km² in the Senoufou greenstone belt, an area recognized for its high gold potential. This licence was previously held in a joint venture (JV) with Barrick Gold, one of the world’s leading gold producers. Historically, greenstone belts have yielded high-grade gold deposits, and the Senoufou belt is no exception. Waraba’s investment signals confidence in the region’s potential for large-scale gold discoveries.
In addition to Sirasso, Waraba Gold gains access to the Tengrela & Tiegba licences, which span a combined area of nearly 767km². These licences are not only prospective for gold but also manganese, a critical mineral in steel production and battery technologies. The proximity of these licences to existing gold mines further enhances their exploration potential.
Under the terms of the agreement, Waraba Gold will gradually acquire an 80% stake in Somaco Global Resources over four years. The investment involves an initial payment of $500,000 to Somaco’s shareholders within the next two months, an additional $1.5 million to be paid over a two-year period, exploration commitments totaling $5 million over the next four years, and the issuance of six million common shares to Somaco shareholders upon the signing of a definitive joint venture agreement.
To finance the initial commitments, Waraba Gold announced plans to raise up to $500,000 through non-convertible unsecured debentures. These funds will also provide general working capital for the company’s operations. In addition, Waraba Gold will appoint two Somaco nominees as directors, further integrating the companies and ensuring a strategic partnership moving forward.
Alongside the Ivory Coast expansion, Waraba Gold provided an update on its Mali operations, revealing that it has temporarily suspended activities at the Fokolore Gold Project due to security concerns. Despite setbacks, Waraba remains committed to the Malian mining sector, having submitted a letter of intent for a mining permit in June 2024. However, with ongoing political instability, the company is waiting for conditions to improve before resuming full-scale operations.
West Africa has emerged as one of the fastest-growing gold mining regions globally, attracting major industry players. However, political uncertainties in countries like Mali have raised concerns among investors. Recently, CEOs of leading gold mining companies stated that Mali’s new mining code requires adjustments to encourage further foreign investment. Regulatory changes will play a crucial role in shaping the future of the region’s mining industry.
Waraba Gold’s agreement with Somaco Global Resources marks a strategic expansion into the Ivory Coast, an increasingly important gold-producing nation. By securing access to high-potential licences, Waraba is positioning itself for long-term growth in the West African mining sector. With ongoing fundraising efforts and a commitment to exploration, Waraba Gold aims to unlock significant value from its new assets. However, challenges in Mali and broader market uncertainties may still impact the company’s overall trajectory in the coming years.
Key Points: – President Trump is set to unveil new auto tariffs, adding to a series of trade measures aimed at reshaping U.S. trade policy. – The White House has confirmed retaliatory tariffs will be applied to several key trading partners. – Global markets are reacting to uncertainty over the scope of these tariffs and their economic impact.
President Donald Trump is set to announce a fresh round of tariffs on auto imports later today, marking another escalation in his administration’s aggressive trade policy. These tariffs come as part of a broader effort to impose retaliatory duties on U.S. trading partners, a move that could significantly impact global trade dynamics.
The announcement follows weeks of speculation regarding which countries will be affected and to what extent. Trump has hinted at providing “a lot of countries breaks,” while also signaling that he does not want “too many” exemptions. The market is closely watching which nations will fall into the “dirty 15” category—those with trade imbalances deemed unfavorable to the United States.
The latest tariffs on automobiles add to an already sweeping list of trade measures enacted by the Trump administration. Earlier this month, a 25% tariff on steel and aluminum imports went into effect, impacting businesses across multiple industries.
The European Union responded swiftly, announcing counter-tariffs on $28 billion worth of U.S. goods. However, implementation has been staggered, with some key measures, like a 50% tariff on American whiskey, delayed until mid-April. This delay has sparked further uncertainty, with Trump threatening a 200% tariff on European spirits in retaliation.
Trump’s trade policies have already significantly impacted Canada and Mexico. As of March 4, the U.S. imposed a 25% tariff on all imports from its neighbors. However, a temporary pause was granted for goods and services that comply with the United States-Mexico-Canada Agreement (USMCA). This exemption is set to expire on April 2, leaving room for renegotiation.
In response, Canada introduced new tariffs on $20 billion worth of U.S. goods, further complicating trade relations. With both countries agreeing to reopen trade discussions, businesses on both sides of the border are bracing for potential disruptions.
Tensions between the U.S. and China remain high as Trump enforces new blanket tariffs of around 20% on top of the existing 10% duties from his first term. China has retaliated with up to 15% duties on U.S. agricultural products, including chicken and pork, which took effect on March 10.
Meanwhile, Venezuela has been targeted with a “secondary tariff” set to take effect on April 2. Under this measure, any country that buys oil or gas from Venezuela will face a 25% tariff when trading with the U.S. This move is expected to isolate Venezuela further while also impacting global energy markets.
The uncertainty surrounding these tariffs is already causing volatility in global markets. Investors are concerned about potential supply chain disruptions, rising costs for consumers, and retaliatory actions from key U.S. trade partners. The auto industry, in particular, could see increased costs, which may trickle down to car buyers in the form of higher prices.
As Trump’s trade war escalates, businesses and investors alike are preparing for a potentially turbulent economic landscape. With April 2—dubbed “Liberation Day” by Trump—fast approaching, all eyes are on the White House for further developments.
